Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122223 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT03122223 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 160 participants.
The verdict
NCT03122223, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ALVAC-HIV (vCP2438)
- BIOLOGICAL Bivalent subtype C gp120/MF59
- BIOLOGICAL Bivalent subtype C gp120/AS01(B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2020-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122223
The ClinicalTrials.gov registry entry for NCT03122223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03122223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122223 about?
NCT03122223 is a clinical study titled "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants". A phase 1/2a clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants
What is the current status of trial NCT03122223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2018-01-16. Estimated completion is 2020-07-30.
What interventions are being tested in trial NCT03122223?
The interventions under investigation include: Placebo (BIOLOGICAL), ALVAC-HIV (vCP2438) (BIOLOGICAL), Bivalent subtype C gp120/MF59 (BIOLOGICAL), Bivalent subtype C gp120/AS01(B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03122223?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.